NSEPress Release1d ago · 13 Oct 2026, 08:33 pm
Press Release
Zydus Lifesciences Limited · ZYDUSLIFE
✦ AI SummaryRegulatory
Zydus Lifesciences Limited has informed the Exchange that the USFDA inspection of its manufacturing plant at Moraiya, Ahmedabad, has concluded with 5 observations. The company will work with the USFDA to address these observations promptly.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk6/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad".
Attachments (1)
📄pdf
Download →
Cadilahc_13102026203320_PressRelease13102026.pdf
View document text
October 13, 2026
BSE Limited Code: 532321
1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001
National Stock Exchange of India Limited Code: Zyduslife
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051
Re.: Press Release
Dear Sir / Madam,
Please find enclosed a copy of press release dated October 13, 2026, titled “USFDA inspection
concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad”.
The contents of the press release give full details.
Please bring the aforesaid news to the notice of the members of the exchange and the
investors’ at large.
Thanking you,
Yours faithfully,
For, Zydus Lifesciences Limited
Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063
Encl.: As above
USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad
Ahmedabad, India, 13 October, 2026
We wish to inform that the USFDA conducted Inspection of the company’s manufacturing plant located
at Moraiya, Ahmedabad. The inspection was conducted from 5th to 13th October 2026.
The inspection closed with 5 observations. The Company will closely work with the USFDA to address
the observations expeditiously.
This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015.